FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 91 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ February 10, 2019 New hormone treatment for advanced prostate cancer made available in England June 8, 2021 “Scars are Tattoos with Better Stories” July 21, 2021 To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome September 9, 2019 Load more HOT NEWS A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity... Frederick National Laboratory for Cancer Research: A Unique Resource for the... FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer...
